Experimental combo shows promise in tough sarcoma
NCT ID NCT05301764
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—LVGN6051, an experimental immune therapy, and anlotinib, a targeted cancer pill—in 39 adults with advanced soft tissue sarcoma that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking at whether the tumors shrank. The study is complete, but results are not yet published.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LVGN6051 (an experimental immune-boosting drug) and anlotinib (a targeted cancer pill)
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for people with advanced soft tissue sarcoma that has not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 39 participants, so the results are preliminary. The combination may cause significant side effects, and the benefit may not be confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Henan cancer hospital
Zhenzhou, Henan, 450008, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, 200233, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Drug duo takes on rare head and neck tumors
- Blood test may spot hidden sarcoma signals
- Vitamin c boosts radiation for sarcoma? early trial shows promise
- Drug combo aims to shrink Hard-to-Treat sarcomas
- Experimental t cell therapy targets sarcoma in small early trial